Amneal Pharmaceuticals (NYSE:AMRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM.
Here's what investors need to know about the announcement.
Earnings
Amneal Pharmaceuticals missed estimated earnings by 7.69%, reporting an EPS of $0.12 versus an estimate of $0.13.
Revenue was up $4.53 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.02 which was followed by a 2.99% increase in the share price the next day.
Here's a look at Amneal Pharmaceuticals's past performance:
| Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|
| EPS Estimate | 0.20 | 0.20 | 0.19 | 0.18 |
| EPS Actual | 0.18 | 0.21 | 0.25 | 0.20 |
| Revenue Estimate | 537.35M | 545.06M | 523.25M | 515.34M |
| Revenue Actual | 536.90M | 528.59M | 535.08M | 493.11M |
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Guidance
Amneal Pharmaceuticals management provided guidance for FY 2022, expecting earnings between $0.8 and $0.85 per share.
To track all earnings releases for Amneal Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
